| 翻訳と辞書 |
Alirocumab
Alirocumab (trade name Praluent)〔( International Nonproprietary Names for Pharmaceutical Substances (INN) ), World Health Organization〕 is a biopharmaceutical drug approved by the FDA in July 24, 2015 as a second line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment. It is a human monoclonal antibody that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety.〔
==Medical uses==
Alirocumab is used as a second line treatment to lower LDL cholesterol for adults who have a severe form of hereditary high cholesterol and people with atherosclerosis who require additional lowering of LDL cholesterol when diet and statin treatment have not worked.〔(Alirocumab label ) Label revised, July 2015. Page accessed July 25, 2015〕 It is administered by subcutaneous injection.〔 As of July 2015, it is not known whether alirocumab prevents early death from cardiovascular disease or prevents heart attacks;〔 a clinical trial to determine outcomes was ongoing at that time,〔 the results of which were expected in 2017.〔
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Alirocumab」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|